EGFR and cancer: Recent studies have shown a high frequency of RAS mutations detected in many human cancers, including NSCLCs, where they are associated with unfavorable prognosis and poor sensitivity to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 3, 4, 5.